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PF573,228 inhibits vascular tumor cell growth, migration 
as well as angiogenesis, induces apoptosis and abrogates 
PRAS40 and S6RP phosphorylation
PF573,228 is a compound that targets focal adhesion kinase 
(FAK), a non-receptor protein kinase, which is over-ex-
pressed in various tumors. The aim of this study was to 
evaluate the effects of PF573,228 on the cells derived from 
mouse vascular tumors, namely, endothelioma cells.
The treatment of endothelioma cells with PF573,228 reduc ed 
their growth with an IC50 of approximately 4.6 µmol L–1 and 
inhibited cell migration with an IC50 of about 0.01 µmol L–1. 
Microscopic studies revealed morphological attributes of 
apoptosis. These observations were confirmed by ELISA, 
which showed increased caspase-3 activity. PF573,228 also 
inhibited angiogenesis in a dose-dependent manner, with 
an IC50 of approximately 3.7 µmol L–1, and abrogated the 
phosphorylation of cell survival proteins, proline-rich Akt 
substrate (PRAS40) and S6 ribosomal protein (S6RP). Array 
data further revealed that PF573,228 induced caspase-3 ac-
tivation, thus promoting apoptosis. Since all the processes 
inhibited by PF573,228 provide important support to tumor 
survival and progression, the drug may have a potential 
role in the treatment of vascular tumors.
Keywords: PF573,228, focal adhesion kinase, endothelioma, 
apoptosis, angiogenesis
PF573,228 is a small molecule that targets the ATP-binding site of focal adhesion kinase 
(FAK) and effectively blocks its catalytic activity in a variety of cell lines (1). Focal adhesion 
kinase is a cytoplasmic tyrosine kinase localized in areas of cell surface that interact with 
neighboring cells and with the extracellular matrix (ECM) (1, 2). It plays an important role 
under various physiological processes that include cell survival and growth, as well as inte-
grin-mediated cell migration (1, 3). However, FAK also promotes these cellular processes in 
pathological conditions such as tumor development and progression (4, 5).
In vitro, vascular tumor cells have been reported to exhibit altered FAK expression 
when compared to normal human dermal microvascular cells, while in patients, FAK 
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seems to promote tumor cell invasion and metastasis (6, 7). Activated FAK leads to activa-
tion of protein kinase B (PKB), thus promoting cell survival and inhibiting apoptosis (8, 9). 
Impaired PKB signaling has been associated with the development of vascular tumors 
(endotheliomas) in mice (10). The proangiogenic factor, vascular endothelial growth factor 
(VEGF), which is implicated in the pathogenesis of vascular tumors like infantile heman-
giomas (IH), uses the PKB signaling pathway to promote cell growth, migration and an-
giogenesis (11).
Treatment of IH and other endothelial neoplasms such as hemangioendotheliomas 
continues to pose a challenge, largely due to the rudimentary knowledge of their patho-
physiology. The endothelioma cells used in this study were derived from murine vascular 
tumors previously employed as a model to study IH and hemangioendotheliomas (10, 12, 
13).
The aim of the study was to investigate the effects of blocking FAK in endothelioma 
cell growth, apoptosis and migration in vitro as well as on angiogenesis ex vivo and on in-
tracellular signaling molecules that regulate cell survival and death.
EXPERIMENTAL
Chemicals and reagents
PF573,228, dimethylsulfoxide (DMSO), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetra-
zolium-bromide (MTT) and Dulbecco’s modified Eagle’s medium (DMEM) were pur-
chased from Sigma-Aldrich, USA. Fetal bovine serum (FBS) was supplied by the Scientific 
Group (SA), while penicillin-streptomycin was purchased from Whitehead Scientific (SA). 
PF573,228 was reconstituted in DMSO, aliquoted and stored at –20 oC. A final concentra-
tion of 0.1 % DMSO was used as a control in all experiments.
Cell culture
Endothelioma (sEnd.2) cells, which were derived from mouse vascular tumors grow-
ing subcutaneously, were provided by Prof. M. S. Pepper (University of Pretoria, South 
Africa). The sEnd.2 cells were maintained in flasks (area 25 cm2) in a humidified atmo-
sphere containing 5 % CO2 at 37 oC. The cells were cultured in DMEM, supplemented with 
10 % FBS and 1 % penicillin-streptomycin.
Cell growth assay
The effects of PF573,228 on endothelioma cells were assessed by determining the per-
centage of viable cells using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium-bro-
mide (MTT) assay. Endothelioma cells were seeded in 96-well plates at a density of 5000 
cells per well overnight, and then treated with PF573,228 (0–10 µmol L–1) for 24 hours. The 
cells were rinsed with phosphate buffered saline (PBS) and 20 µL MTT was added to each 
well. After 4 hours of incubation, MTT crystals were dissolved with addition of acidic 
isopropanol (100 µL per well). The absorbance was read at 570 nm on an ELx 800 Universal 
Microplate Reader (Bio-Tek instruments Inc, SA).
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Hematoxylin and eosin staining
Endothelioma cells were seeded on heat-sterilized cover slips in 6-well plates at a 
density of 3×105 cells per well overnight. The cells were treated with PF-573,228 (0–10 µmol 
L–1) over a period of 24 hours and then stained with hematoxylin and eosin (H&E) using 
the previously described method (10). The cells were fixed in Bouin’s fluid. After 30 min-
utes of fixing, they were rinsed in 70 % ethanol for a further 30 minutes, and then rinsed 
with water. The cells were immersed in Meyer’s haemalum for 20 minutes, rinsed with 
water for two minutes, followed by 70 % ethanol. The cells were incubated for two minutes 
in 1 % eosin and then rinsed twice with increasing concentrations of ethanol (70, 96 and 
100 %). Xylol was used to rinse the cells twice before mounting them onto microscopic 
glass slides using resin. The slides were viewed with an Olympus BX63 light microscope 
(Wirsam Scientific, SA) and images were captured using the Olympus DP72 digital camera 
(Wirsam Scientific).
Transmission electron microscopy
The sEnd.2 cells were treated with 0–10 µmol L–1 PF-573,228 for 24 hours and then pro-
cessed for transmission electron microscopy (TEM) using a standard protocol as described 
previously (13). Mounted sections were then viewed using TEM (Apollo Scientific, SA).
Caspase activity
Endothelioma cells were seeded in 6-well plates at a density of 3×105 cells per well and 
allowed to attach overnight. The cells were treated with PF573,228 at the indicated doses 
for 24 hours. Caspase-3 activity was measured using a commercially available kit accord-
ing to the manufacturer’s instructions (BioVision, Mountain View, USA).
Cell migration
Cell migration was measured using xCELLigence Real Time Cell Analysis (RTCA) 
instrument, which measures the electrical impedance of migrating cells and records it as 
the cell index (CI) value. The CI value is derived from the relative change in electrical 
impedance over time. Medium supplemented with 10 ng L–1 basic fibroblast growth factor 
(bFGF) was introduced to the bottom chambers of the cell invasion and migration (CIM) 
plates. Prior to the seeding of cells, 50 µL of serum free medium was added to the top 
chamber of each CIM plate.
The plates were then allowed to equilibrate for 60 minutes at 37 °C before a back-
ground measurement was taken using the RTCA instrument. Endothelioma cells were 
then added to the top chambers of the plates at a density of 6000 cells per well and treated 
with PF573,228 (0–10 µmol L–1). Cell migration was monitored for 21 hours. Results are 
represented as the cell index (CI) without normalization.
Aorta ring assay
Aortas were harvested from 6–8 week old male Sprague-Dawley rats, cleaned by re-
moving periaortic fibrofatty tissue and blood clots using scissors and fine forceps. The 
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aortas were cut into 1-mm wide rings and transferred into Petri-dishes with fresh, serum-
free, MCDB-131 medium. The rings were then embedded in fibrin gel in 24-well culture 
plates. The cultures were maintained in MCDB-131 medium supplemented with 0.3 mg 
mL–1 amino caproic acid and 1 % penicillin/streptomycin solution. The cultures were treat-
ed with PF573,228 (0–10 µmol L–1) for 10 days. Medium and drugs were renewed every 2 
days. Cultures were monitored for growth every second day using a Zeiss Axiovert micro-
scope (Carl Zeiss, Germany) attached to a digital camera.
Ethical approval was obtained from the University of Pretoria’s Animal Use and Care 
Committee.
Antibody array studies
The phosphorylation/activation status of eighteen signaling molecules was investi-
gated using an intracellular signaling array kit (Cell Signaling, USA). The assay was un-
dertaken according to the manufacturer’s protocol. Glass slides were imaged using the 
Fluorchem E System (ProteinSimple, USA).
Data analysis
Statistical analysis was undertaken using the analysis of variance (ANOVA)-single 
factor model, followed by Tukey’s ad hoc test, using the GraphPad Software version 4.00. 
The data are mean ± SD unless stated otherwise, and differences were taken to be statisti-
cally significant at p < 0.05.
RESULTS AND DISCUSSION
Effects of PF573,228
Cell growth. – The results showed that PF573,228 had little effect on the percentage of 
viable endothelioma cells at low concentrations (0.1 µmol L–1 and below) when compared to 
the controls (Fig. 1). At concentrations of 1 µmol L–1 and above, the drug induced a signifi-
cant decrease in cell growth (p < 0.05), with an IC50 value of approximately 4.6 µmol L–1 (Fig. 
1). Previous studies have shown that PF573,228 induced a significant inhibition of human 
umbilical vein endothelial cell (HUVEC) survival, although this was achieved at lower 
doses (14). Since the cells used in this study were not primary cells like HUVEC, but rath-
er tumor cells, it is plausible that the cells could have been resistant. Indeed, previous 
studies have shown that protein kinase B (PKB), a downstream activator of FAK, was up-
regulated in endothelioma cells (10). This protein promotes cell survival (10). Inhibition of 
FAK phosphorylation could account for the observed decrease in cell growth, since the 
phosphorylation of FAK promotes cell survival and proliferation (14–16). To better under-
stand the growth inhibitory effects of PF573,228 on these vascular tumor cells, the mor-
phology of the cells was studied.
Cell morphology. – A monolayer of cells was observed in both the control and 1 µmol 
L–1 PF573,228-treated cultures, although control cells appeared denser (Fig. 2). Also, con-
trol cells were in different phases of mitosis, while drug treated cells (1 µmol L–1) were 
mostly in interphase (Fig. 2). Thus, the decrease in the percentage of viable cells in cultures 
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treated with 1 µmol L–1 of the drug compared to the controls may have been largely due to 
reduced cell division rather than cell death. Indeed, H&E images showed increased mi-
totic activity in control cultures and not in cultures treated with 1 µmol L–1 PF573,228.
Fig. 1. Effect of PF573,228 on endothelioma cell growth. Data represent the mean of three wells ± SD 
from three separate experiments (*p < 0.05 compared to the control).
Fig. 2. Effect of PF573,228 on endothelioma cell morphology. Representative images of H&E stained 
control cells as well as cells treated with 1 and 10 µmol L–1 PF573,228.
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At 10 µmol L–1 of PF573,228, the cells seemed to have lost cell-cell contact. Since FAK 
is a protein that promotes cell-cell adhesion, it is not surprising that its inhibition dis-
rupted cell-cell contact. Cells also appeared round in shape, with dark features that looked 
like condensed chromatin. To ascertain whether the observed dark features in H&E 
stained cells reflected chromatin condensation, transmission electron microscopy was em-
ployed. 
Micrographs from TEM studies revealed elongated cells with typical endothelial cell 
morphology in control and 1 µmol L–1 PF573,228-treated cultures (Figs. 3a–d). Membranes 
of the cells in these cultures appeared smooth, without any attributes of blebbing (mem-
brane blebbing is one of the early characteristics of apoptosis). Also, the nuclei of these cells 
had a normal appearance. In cultures treated with 10 µmol L–1 PF573,228, condensed chro-
matin was observed (Figs. 3e,f). These findings confirmed H&E observations. Further-
more, TEM micrographs showed cells with hypervacuolization (Figs. 3e,f). Both chromatin 
condensation and hypervacuolization are features of apoptotic cell death (17). Therefore, 
a caspase activity assay was employed to further determine potential apoptosis.
Caspase-3 activity. – At low doses of PF573,228, there was no effect on caspase-3 activ-
ity (Fig. 4). At 1 µmol L–1, there was a marginal increase in caspase activity. A significant 
Fig. 3. PF573,228 induces apoptosis in endothelioma cells. Representative TEM micrographs of: a) and b) 
control endothelioma cells; c) and d) cells treated with 1 µmol L–1 and e) and f) 10 µmol L–1 PF573,228, re-
spectively.
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increase in the activation of caspase-3 (p < 0.001) was observed following the treatment of 
cells with 10 µmol L–1 of the drug (Fig. 4). Since activated caspase-3 executes apoptosis, 
these observations indicate that the pronounced decrease in cell growth observed follow-
ing the exposure of cells to 10 µmol L–1 PF573,228 may be due, at least in part, to the induc-
tion of apoptosis by the drug.
Fig. 4. Effect of PF573,228 on the activity of caspase-3 in endothelioma cells. Values (in arbitrary units) 
are mean ± SD from three experiments (**p < 0.001 compared to the control).
Fig. 5. PF573,228 inhibits endothelioma cell migration. Data are shown as the mean CI of four wells ± 
SD. Three independent measurements were conducted (**p < 0.001 compared to the control).
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Cell migration. – Focal adhesion kinase has previously been shown to modulate cell 
migration, particularly during angiogenesis (3). Therefore, the effects of blocking FAK 
with PF573,228 on cell migration were investigated using real time cell analysis. The re-
sults showed a significant decrease in the amount of cells that migrated from the top to the 
bottom chamber of the CIM plates following drug treatment when compared to the con-
trols (p < 0.001), even at doses as low as 0.1 µmol L–1 (Fig. 5). The effects of PF573,228 on cell 
migration were dose-dependent, with an IC50 of about 0.01 µmol L–1 (Fig. 5). The effects of 
PF573,228 on cell migration were dose-dependent, with an IC50 of about 0.0128 µmol L–1 
(Fig. 5). It has been reported that following the binding of the proangiogenic factor, vascu-
lar endothelial growth factor (VEGF), to the vascular endothelial growth factor receptor-2 
(VEGFR-2), Src kinase, one of the downstream signaling molecules for VEGF, is recruited 
and activated, resulting in phosphorylation of FAK (18, 19). This, in turn, leads to increased 
Fig. 6. PF573,228 reduces neovessel growth. Representative images of: a) control culture showing an 
aorta ring with microvessels emanating from its surface, b) an aorta ring treated with 10 µmol L–1 of 
PF573,228 showing a reduced area of neovessel growth (bar 250 µm). c) Graph showing the dose-
dependent effects of PF573,228 on microvessel growth in aorta ring cultures. Data represent the mean 
of three wells ± SD. Three separate measurements were undertaken (*p < 0.05 compared to the control).
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endothelial cell migration (18, 19). In addition, FAK-induced cell migration has been associ-
ated with the development of various neoplasms (2, 20). Thus, the blocking of FAK is a 
plausible target for therapeutic inhibition of cell motility, and perhaps of angiogenesis, 
since endothelial cell migration is crucial during the angiogenic process.
Angiogenesis. – Angiogenesis was evaluated using the aorta ring assay. In control cul-
tures, aorta rings gave rise to neovessels; representative images are shown in Fig. 6a. The 
area of neovessel growth was reduced in cultures treated with PF573,228 (Fig. 6b). These 
observations were confirmed by quantitative analysis (Fig. 6c) which revealed that the 
drug induced a significant inhibition of angiogenesis at doses of 1 and 10 µmol L–1 (p < 0.05). 
PF573,228 induced a dose-dependent inhibition of neovessel growth with an approx. IC50 
of 3.7 µmol L–1. Focal adhesion kinase is required for tumor angiogenesis (20, 21). There-
fore, FAK may be an important target in the abrogation of tumor angiogenesis, especially 
in the context of problematic vascular tumors such as infantile hemangiomas (IH) and 
hemangioendotheliomas.
Intracellular signaling proteins. – Phosphorylated proline-rich Akt-substrate 40 (PRAS40), 
a substrate of protein kinase B (PKB), was detected in control cells (Fig. 7). PF573,228 inhib-
ited PRAS40 phosphorylation (Fig. 7). PRAS40 is phosphorylated by PKB (22, 23). In turn, 
phosphorylated PRAS40 promotes cell survival (22).
In the present study, phosphorylated S6 ribosomal protein (S6RP) was detected in 
control cells but not in the drug-treated cultures. These observations show that blocking 
FAK with PF573,228 inhibits S6RP phosphorylation. Focal adhesion kinase functions to 
phosphorylate S6RP (24, 25), thus activating this important effector of cell growth (25). 
Taken together, the drug blocks the phosphorylation of intracellular signaling molecules 
(PRAS40 and S6RP) that promote the growth of tumor cells.
Fig. 7. Images captured by the Fluorchem E system showing the effects of PF573,228 on the phos-
phorylation/activation status of various intracellular signaling proteins: a) S6RP, b) PRAS40, c) 
cleaved caspase-3.
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The current studies also showed that cleaved caspase-3 was detected in PF573,228-
treated cultures while the activated form of this protein was not detected in control cul-
tures (Fig. 7). Proteolytic cleavage of inactive caspase-3 results in the formation of the ac-
tivated form of this protease, which enables it to participate in the execution of apoptosis 
(17, 26). These array results on caspase-3 correlate with the caspase-3 ELISA assay, which 
showed increased caspase-3 activation in the drug-treated cells. Furthermore, microscopy 
observations showed morphological features of apoptosis in endothelioma cells treated 
with 10 µmol L–1 PF573,228. Taken together, these observations indicate that PF573,228- 
induced apoptosis may be caspase dependent.
Furthermore, PF573,228 may have a role in the elaboration of targeted therapeutic ap-
proaches for vascular lesions characterized by the overexpression of S6RP and PRAS40.
CONCLUSIONS
The data obtained from this study suggests that FAK blockade results in the inhibition 
of processes that are of essential benefit to the growth and progression of vascular tumors, 
namely, tumor cell growth, migration as well as angiogenesis. Endothelioma cell apoptosis 
was also induced, albeit at much higher doses.
Considering that growth-promoting proteins are overexpressed in control tumor 
cells, it is plausible that they might contribute to the development of tumors. Thus, S6RP 
and PRAS40 could be potential therapeutic targets. Furthermore, the correlation of FAK 
inhibition with decreased cell migration and angiogenesis at non-cytotoxic doses makes 
FAK an attractive target for combination approaches aimed at the treatment of vascular 
tumors.
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